DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Eloxatin (Oxaliplatin) - Summary

 
 



WARNING

ELOXATIN (oxaliplatin injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

Anaphylactic-like reactions to ELOXATIN have been reported, and may occur within minutes of ELOXATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms (see WARNINGS and ADVERSE REACTIONS).

 

ELOXATIN SUMMARY

ELOXATIN(oxaliplatin for injection) is an antineoplastic agent. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.

ELOXATIN, used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.


See all Eloxatin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Eloxatin (Oxaliplatin)

New data supports first-line use of Vectibix for metastatic colorectal cancer
Source: Colorectal Cancer News From Medical News Today [2015.01.20]
Amgen has announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy...

Favorable OS rates for rectal cancer patients demonstrated by secondary analysis of RTOG 0247
Source: Radiology / Nuclear Medicine News From Medical News Today [2015.01.13]
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of...

Tumor location in colorectal cancer may influence survival
Source: Colorectal Cancer News From Medical News Today [2015.02.26]
The two halves of the human colon have different embryonic origins and gene expression patterns, and these differences may also play a role in cancer biology, according to a study published in the...

Keck Medicine of USC researchers trace origins of colorectal cancer tumor cells
Source: Colorectal Cancer News From Medical News Today [2015.02.12]
Big Bang' model of tumor growth provides view into how to stop cancer before it startsFor the first time, Keck Medicine of the University of Southern California (USC) cancer researchers have...

Colorectal cancer survivors who smoke 'have double risk of death'
Source: Colorectal Cancer News From Medical News Today [2015.02.04]
Study finds that colorectal cancer survivors who smoke have twice the risk of death compared to non-smoking counterparts, adding to evidence of links between smoking and cancer.

more news >>

Published Studies Related to Eloxatin (Oxaliplatin)

Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). [2014]
whether calcium/magnesium decreases oxaliplatin-related neurotoxicity... CONCLUSION: This study does not support using calcium/magnesium to protect

Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. [2013]
hyperexcitability and acute neurotoxicity symptoms are unclear... CONCLUSIONS: Ca/Mg infusions do not alter the clinical pharmacokinetics of

Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. [2011.07.10]
PURPOSE: To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer... CONCLUSION: Adding oxaliplatin to fluorouracil-based preoperative chemoradiotherapy significantly increases toxicity without affecting primary tumor response. Longer follow-up is needed to assess the impact on efficacy end points.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.07]
BACKGROUND: When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to achieve this aim... INTERPRETATION: Although this trial did not show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in terms of overall survival, chemotherapy-free intervals remain a treatment option for some patients with advanced colorectal cancer, offering reduced time on chemotherapy, reduced cumulative toxic effects, and improved quality of life. Subgroup analyses suggest that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemotherapy and should not receive a treatment break. FUNDING: Cancer Research UK. Copyright (c) 2011 Elsevier Ltd. All rights reserved.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.06.18]
BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival... INTERPRETATION: This trial has not confirmed a benefit of addition of cetuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorectal cancer. Cetuximab increases response rate, with no evidence of benefit in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional mutational analysis of their tumours. The use of cetuximab in combination with oxaliplatin and capecitabine in first-line chemotherapy in patients with widespread metastases cannot be recommended. FUNDING: Cancer Research UK, Cancer Research Wales, UK Medical Research Council, Merck KGgA. Copyright (c) 2011 Elsevier Ltd. All rights reserved.

more studies >>

Clinical Trials Related to Eloxatin (Oxaliplatin)

XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer [Active, not recruiting]
XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be randomized to standard XELOX (Capecitabine 1000 mg/m˛ in the morning and 1000 mg/m˛ in the evening days 1-14 and short term Oxaliplatin 130 mg/m˛ day 1 in 30 minutes) or chronomodulated XELOX (Capecitabine 400 mg/m˛ in the morning and 1600 mg/m˛ in the evening days 1-14 and short term Oxaliplatin 130 mg/m˛ day 1 in 30 minutes).

Bloodsamples will be collected and frozen and later examined for potential predictive factors

Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer [Recruiting]
The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal cancer.

Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer [Recruiting]
Primary objective :

To compare the combination of S-1 and oxaliplatin(SOX) to the combination of capecitabine and oxaliplatin(COX) therapy for advanced or metastatic colorectal carcinoma.

Secondary objectives :

1. To evaluate and compare the efficacy (overall survival and response rate) in the two treatment groups.

2. To evaluate and compare the quality of life of the patients and safety profiles of the two treatment groups.

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib [Recruiting]
The primary purpose of this study is to find the highest tolerated dose of the study drugs: capecitabine, oxaliplatin, bevacizumab, and dasatinib given in combination to subjects with advanced solid tumors. This will occur in the first part of the study (Phase I). Once this dose has been determined, it will be given to subjects with advanced metastatic colorectal cancer in the second part of the study (Phase II).

By giving these drugs in combination, researchers hope to evaluate the side effects of the study drugs in both groups, and to determine if this combination could possibly decrease or stabilize the cancer being treated.

Subjects will be enrolled at Duke University Medical Center (DUMC) and Rocky Mountain Cancer Center.

After satisfying eligibility and screening criteria, patients will be treated on 21 day cycles.

ABOUT THE STUDY DRUGS

- Capecitabine (Xeloda™) is an oral (taken by mouth) chemotherapy drug in tablet form

made by Roche Laboratories Inc. Capecitabine has been approved for use by the Food and Drug Administration (FDA) for first line treatment (treatment that should be used for cancer that has not been treated yet) of metastatic colorectal cancer and also for metastatic breast cancer.

- Oxaliplatin (Eloxatin™) is an intravenous (given by injection into a vein) chemotherapy

drug made by Sanofi-Synthélabo. This drug is also approved by the FDA for use in metastatic colorectal cancer.

- Bevacizumab (Avastin™) is a type of intravenous cancer treatment called anti-angiogenic

therapy (a type of therapy to treat cancer that interferes with blood flow to the tumor, thereby stopping tumor growth, and possibly leading to tumor shrinkage) made by Genentech Inc. Bevacizumab is approved by the FDA for first line treatment of metastatic colorectal cancer in combination with other chemotherapy.

- Dasatinib (Sprycel™) is an oral drug made by BMS, Inc. Dasatinib is approved by the

FDA for the treatment of chronic myeloid leukemia (CML), acute lymphoblastic leukemia or for patients that are resistant to a medicine called imatinib mesylate (Gleevec™ ).

Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma [Active, not recruiting]
This is a Phase II trial of the combination of oxaliplatin (Eloxatin) and capecitabine (Xeloda), known as XELOX, in patients with unresectable or recurrent cholangiocarcinoma, including carcinoma of the gallbladder or biliary tract, both intrahepatic and extrahepatic. Patients may be either previously untreated or treated with chemotherapy. Patients will accrue to two strata based on pre-treatment status; separate response rates and statistical operating characteristics will be applied to each stratum.

The primary objective is to determine the objective response rate (complete plus partial) of XELOX in this population.

Secondary objectives include determining toxicity, stable disease rates, and median and overall survival of patients treated with this combination.

more trials >>

Reports of Suspected Eloxatin (Oxaliplatin) Side Effects

Death (26)Dyspnoea (25)Diarrhoea (23)Nausea (21)Abdominal Pain (18)Vomiting (17)Anaemia (15)Renal Failure Acute (12)Hypertension (12)Asthenia (12)more >>


Page last updated: 2015-02-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015